1. Home
  2. MATH vs ANVS Comparison

MATH vs ANVS Comparison

Compare MATH & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.09

Market Cap

47.5M

Sector

Finance

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.19

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
ANVS
Founded
2015
2008
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.5M
50.4M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
MATH
ANVS
Price
$1.09
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $10.50
AVG Volume (30 Days)
206.7K
★ 1.1M
Earning Date
08-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.04
52 Week High
$4.08
$5.50

Technical Indicators

Market Signals
Indicator
MATH
ANVS
Relative Strength Index (RSI) 63.42 38.01
Support Level $1.05 $1.04
Resistance Level $1.17 $2.43
Average True Range (ATR) 0.08 0.09
MACD 0.01 0.02
Stochastic Oscillator 92.67 38.46

Price Performance

Historical Comparison
MATH
ANVS

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: